Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.
Oncolytic virus is not necessarily a competitor of standard therapies that are already present in the market such as CAR-T or checkpoint inhibitors. Oncolytic virus works synergistically with those technologies and, if used together, can significantly enhance therapeutic efficacy.
